New York, Feb 5, 2026, 08:54 a.m. EST — Premarket
- BSX climbed roughly 1% in pre-market trading following a 17.6% drop on Wednesday
- Electrophysiology sales fell short of expectations, and a weaker 2026 forecast sparked the selloff
- Attention turns to U.S. demand data ahead of the open
Boston Scientific shares ticked up roughly 1% in Thursday’s premarket, recovering some ground after a sharp slide the previous day. The stock hovered near $76.30, up from Wednesday’s $75.50 close.
This shift carries weight since the company’s electrophysiology segment has been the engine behind BSX’s reputation as a medtech growth leader. Once that drive falters, the entire narrative tends to get repriced quickly.
The timing of the guidance is, frankly, awkward. The first-quarter outlook will swiftly show whether Wednesday’s sell-off was just a blip or the beginning of a more serious slide.
Boston Scientific reported a 15.9% jump in fourth-quarter net sales, hitting $5.286 billion. Adjusted earnings came in at 80 cents per share. The company’s outlook for 2026 includes 10% to 11% organic net sales growth, excluding currency impacts and certain acquisitions, with adjusted EPS expected between $3.43 and $3.49. For the first quarter, Boston Scientific anticipates organic growth of 8.5% to 10%, and adjusted EPS in the range of 78 to 80 cents.
Shares fell Wednesday after electrophysiology sales came in at $890 million in Q4, below RBC’s $933 million estimate. Watchman sales also slipped about 1% short of projections, dragged down by softer demand in the U.S., analysts noted. “Their worries were not misplaced,” said Citi’s Joanne Wuensch. J.P. Morgan echoed those concerns, suggesting investors reassess growth potential in both segments. Still, CEO Michael Mahoney expressed he was “really pleased” with 35% organic growth in electrophysiology and forecasted the market to expand around 15% by 2026. Reuters
On the earnings call, Mahoney said “our results in Q4 exceeded our internal target” but pushed back against what he called overly optimistic growth assumptions for the U.S. electrophysiology market. CFO Jonathan Monson pointed to challenges in the first-quarter outlook, highlighting the discontinuation of ACURATE and a short-term impact from pulling certain sizes of the AXIOS device used in endoscopy. The Motley Fool
BSX closed Wednesday off 17.6%, tumbling from an intraday peak of $81.78 down to $75.00. Trading volume hit roughly 78.2 million shares.
The broader market edged lower before the open. The S&P 500 ETF slipped roughly 0.5% in early action, while a U.S. medical devices ETF plunged nearly 1.9%.
Electrophysiology is a packed field, with Abbott and Medtronic vying fiercely for control of ablation and mapping systems aimed at atrial fibrillation. The Watchman stroke-prevention device deals with stiff competition too, meaning any decline in U.S. demand is swift and pronounced.
The risk is clear: if U.S. electrophysiology demand remains uneven and pricing pressure worsens, the company might miss its highest 2026 growth targets. A weak quarter from Watchman would weigh on the stock, no matter how the broader indexes perform.
Boston Scientific filed its earnings report in a Form 8-K on Wednesday. Investors typically turn to this document to examine segment details and better understand the factors behind the “adjusted” EPS number. SEC
The earnings call ended, shifting focus to the New York open at 9:30 a.m. ET. Traders will be keeping an eye on whether the stock can stay above Wednesday’s $75 low as regular-session volume picks up.
